Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches designed to address hard-to-treat tumors. BioNTech also develops vaccine candidates and other immune-modulating treatments aimed at preventing or managing serious infectious diseases. Its work spans multiple platforms, including mRNA, protein-based therapies, and next-generation immunomodulators, reflecting a broad research and development base. BioNTech SE serves a central role in the biopharmaceutical market by advancing precision medicine approaches that combine molecular science with clinical development, supporting both preventative and therapeutic applications across global healthcare markets.
€90.25
€0.64 (-0.70%)
EOD Jun 22, 2026 · Twelve Data
The business is unprofitable at the operating level (-22.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.3%, steady but not accelerating.
Negative free cash flow of -€293M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€2.81B
▲ +4.3% YoY
Net Income (TTM)
-€1.25B
▼ -70.8% YoY
Op. Margin
-27.67%
▼ -0.7pp YoY
ROIC
-2.59%
▼ -0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€606M
▼ -19.8% YoY
Op. Cash Flow (TTM)
€706M
▼ -39.5% YoY
Net Debt
-€14.61B
Net Cash Position
Cash & Equiv.
€14.88B
3Y CAGR: -45.1%
Continue Research